Latest News and Events
Filter by
Selections
January 7, 2019
Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-ANG3 for Treatment of Dyslipidemias and Metabolic Diseases
Read MoreJanuary 7, 2019
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia
Read MoreDecember 17, 2018
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Read MoreNovember 9, 2018
Arrowhead Pharmaceuticals Presents Late-Breaking Preliminary Clinical Data on ARO-HBV at Liver Meeting® 2018
Read MoreNovember 9, 2018